Abstract Number: 1118 • 2014 ACR/ARHP Annual Meeting
Olecranon Bursitis Is Often Hemorrhagic and Responds to Steroid Injections
Background/Purpose . Olecranon bursitis is a common presentation to an outpatient rheumatology practice. The differential diagnosis includes crystalline bursitis (gout and pseudogout), inflammatory bursitis due…Abstract Number: 919 • 2014 ACR/ARHP Annual Meeting
Glucocorticoid Exposure and Fracture Risk in a Large Cohort of Commercially-Insured Rheumatoid Arthritis Patients Under Age 65
Background/Purpose Systemic glucocorticoid use can increase fracture risk, although dose-specific effects are not well understood, especially in younger adults. Underlying diseases (e.g., rheumatoid arthritis [RA])…Abstract Number: 824 • 2014 ACR/ARHP Annual Meeting
Impact of Oral Glucocorticoid Therapy on Mortality in Patients with Rheumatoid Arthritis and Diabetic Mellitus
Background/Purpose Glucocorticoid (GC) therapy is known to increase the risk of new-onset type 2 diabetes mellitus (DM). Furthermore, GC therapy increases blood glucose in diabetic…Abstract Number: 29 • 2014 ACR/ARHP Annual Meeting
Impaired Bone Healing in Patients Suffering from Rheumatoid Arthritis – Anti-Inflammatory Therapy As Confounder
Background/Purpose Anti-inflammatory treatment of rheumatoid arthritis (RA) with glucocorticoids (GC) and/or non-steroidal anti-inflammatory drugs (NSAIDs) is supposed to negatively influence bone metabolism and healing. It…Abstract Number: L13 • 2014 ACR/ARHP Annual Meeting
Monthly Ibandronate Reduces Bone Loss in Osteopenic Women with Rheumatoid Arthritis Receiving Long-Term Glucocorticoids: A 48-Week Double-Blinded Randomized Placebo-Controlled Investigator-Initiated Trial
Background/Purpose: Long-term use of glucocorticoids (GC) is problematic for patients with increased risk for vertebral fractures, especially those with rheumatoid arthritis (RA). Thus, prevention of…Abstract Number: 2913 • 2014 ACR/ARHP Annual Meeting
Does Corticosteroid Therapy at Disease Onset Influence Disease Progression of RA? Results from the Swiss Prospective Observational Cohort
Background/Purpose Anti-inflammatory and disease-modifying properties of glucocorticoids (GCs) have been demonstrated in patients with rheumatoid arthritis (RA). Better outcomes in trials by combinations of synthetic…Abstract Number: 2375 • 2014 ACR/ARHP Annual Meeting
Should Physician Reduce patients’ Glucocorticoids to Offset the Risk of Serious Infection Event Among RA Patients Who Switched from Non-Biologic Dmards and Glucocorticoid to Biologics?
Background/Purpose: Glucocorticoids (GCs) and biologic disease-modifying antirheumatic drugs (DMARDs) have previously been associated with serious infection events (SIEs) among rheumatoid arthritis (RA) patients. For patients…Abstract Number: 2225 • 2014 ACR/ARHP Annual Meeting
Does Previous Corticosteroid Treatment Affect the Inflammatory Infiltrate Found in Polymyositis Muscle Biopsies?
Background/Purpose: We conducted this study because there have been no studies evaluating the effect of the use of corticosteroids (CE) on the presence of inflammatory…Abstract Number: 2336 • 2013 ACR/ARHP Annual Meeting
Phase 2 Evaluation Of PF-04171327, a Dissociated Agonist Of The Glucocorticoid Receptor, For The Treatment Of Rheumatoid Arthritis In Patients With An Inadequate Response To Methotrexate
Background/Purpose: PF-04171327, a pro drug of PF-00251802, is under investigation as a potential dissociated agonist of the glucocorticoid receptor (DAGR). PF-00251802 is a selective high-affinity…Abstract Number: 2081 • 2013 ACR/ARHP Annual Meeting
Role Of Muscle Persistent CD28null T Cells In Glucocorticoid Therapy Resistance In Myositis Patients
Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) are characterized by infiltration of T cells and macrophages in skeletal muscle tissue. Conventional immunosuppressive treatment has limited effects…Abstract Number: 1693 • 2013 ACR/ARHP Annual Meeting
Initial Triple DMARD Therapy Is More Efficient Than Methotrexate Monotherapy In Recent Onset Rheumatoid Arthritis; 1-Year Data Of a Randomized Clinical Trial (tREACH)
Background/Purpose: Recommended treatment for DMARD naïve patients is methotrexate (MTX) with or without glucocorticoids (GCs). Triple DMARD therapy however is not recommended, because well proven…Abstract Number: 1663 • 2013 ACR/ARHP Annual Meeting
Obese Polymyalgia Rheumatica Patients Experience More Pain and Disability and Need Higher Doses Of Glucocorticoids
Background/Purpose: Obesity is not only a risk factor for osteoarthritis but also for rheumatoid arthritis (RA). In obese RA patients, disease incidence is higher and…Abstract Number: 1479 • 2013 ACR/ARHP Annual Meeting
Relationship Between physicians’ Decision To Use Concomitant Glucocorticoid and Remission During Treatment With Tocilizumab In Patients With Background Of Limited Dose Of MTX
Background/Purpose: Now, predictive factors at baseline for the good outcome of treatment with biologics are very important not to waste time to treatment goal “remission”.…Abstract Number: 1420 • 2013 ACR/ARHP Annual Meeting
Induction Therapy With Adalimumab On Top Of An Aggressive Treat-To-Target Strategy With Methotrexate and Intraarticular Corticosteroid Reduces Radiographic Erosive Progression In Early Rheumatoid Arthritis, Even After Withdrawal Of Adalimumab. Results Of a 2-Year Trial (OPERA)
Background/Purpose: In a randomized double-blind, placebo-controlled 2-year investigator-initiated trial of patients with early rheumatoid arthritis¹ (RA) we aimed to investigate if additional adalimumab (ADA) for…Abstract Number: 1218 • 2013 ACR/ARHP Annual Meeting
Incidence Of and Risk Factors For Clinical Fractures In Patients With Systemic Lupus Erythematosus and Matched Controls: A Population-Based Study In The United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) has been associated with an increased risk of low bone mineral density and fractures. However, data on absolute fracture risk…
ACR Meeting Abstracts